Sephy Philip

1.5k total citations
57 papers, 1.1k citations indexed

About

Sephy Philip is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Nutrition and Dietetics. According to data from OpenAlex, Sephy Philip has authored 57 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Surgery, 32 papers in Endocrinology, Diabetes and Metabolism and 17 papers in Nutrition and Dietetics. Recurrent topics in Sephy Philip's work include Lipoproteins and Cardiovascular Health (35 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (28 papers) and Fatty Acid Research and Health (17 papers). Sephy Philip is often cited by papers focused on Lipoproteins and Cardiovascular Health (35 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (28 papers) and Fatty Acid Research and Health (17 papers). Sephy Philip collaborates with scholars based in United States, Canada and France. Sephy Philip's co-authors include Craig Granowitz, Peter P. Tóth, Michael Hüll, Ralph T. Doyle, Rebecca A. Juliano, Kristi Reynolds, Gregory A. Nichols, Sergio Fazio, Christie M. Ballantyne and Wenjun Fan and has published in prestigious journals such as Nucleic Acids Research, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Sephy Philip

55 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sephy Philip United States 18 569 557 367 295 125 57 1.1k
James M. Backes United States 17 482 0.8× 227 0.4× 126 0.3× 148 0.5× 132 1.1× 43 923
P. Mata Spain 14 530 0.9× 269 0.5× 112 0.3× 274 0.9× 50 0.4× 36 967
David Colquhoun Australia 11 631 1.1× 341 0.6× 341 0.9× 74 0.3× 125 1.0× 16 1.1k
Helmut Schulte Germany 7 795 1.4× 817 1.5× 370 1.0× 91 0.3× 171 1.4× 7 1.4k
Bernard M. Wolfe Canada 15 331 0.6× 501 0.9× 565 1.5× 142 0.5× 90 0.7× 25 1.2k
Andrey V. Susekov Russia 6 353 0.6× 239 0.4× 182 0.5× 113 0.4× 55 0.4× 24 564
Sion Roy United States 13 351 0.6× 144 0.3× 329 0.9× 182 0.6× 63 0.5× 75 860
Estelle Nobécourt France 17 604 1.1× 621 1.1× 179 0.5× 54 0.2× 173 1.4× 43 1.3k
Giacomo Levantesi Italy 18 205 0.4× 235 0.4× 548 1.5× 216 0.7× 87 0.7× 27 1.3k
Christos V. Rizos Greece 19 392 0.7× 601 1.1× 165 0.4× 50 0.2× 181 1.4× 42 1.3k

Countries citing papers authored by Sephy Philip

Since Specialization
Citations

This map shows the geographic impact of Sephy Philip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sephy Philip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sephy Philip more than expected).

Fields of papers citing papers by Sephy Philip

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sephy Philip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sephy Philip. The network helps show where Sephy Philip may publish in the future.

Co-authorship network of co-authors of Sephy Philip

This figure shows the co-authorship network connecting the top 25 collaborators of Sephy Philip. A scholar is included among the top collaborators of Sephy Philip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sephy Philip. Sephy Philip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Derington, Catherine G., Adam P. Bress, Jennifer S. Herrick, et al.. (2022). The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. SHILAP Revista de lepidopterología. 10. 100345–100345. 6 indexed citations
2.
Olshansky, Brian, Mina K. Chung, Matthew J. Budoff, et al.. (2020). Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. European Heart Journal Supplements. 22(Supplement_J). J34–J48. 72 indexed citations
3.
4.
Fan, Wenjun, Sephy Philip, Craig Granowitz, Peter P. Tóth, & Nathan D. Wong. (2020). Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014. Cardiology and Therapy. 9(1). 207–213. 47 indexed citations
5.
Aberra, Tsion, Eric D. Peterson, Neha J. Pagidipati, et al.. (2020). The association between triglycerides and incident cardiovascular disease: What is “optimal”?. Journal of clinical lipidology. 14(4). 438–447.e3. 62 indexed citations
6.
Leatherman, Sarah, Ryan Ferguson, Cynthia Hau, et al.. (2020). RESIDUAL CARDIOVASCULAR RISK IN U.S. VETERANS WITH MODERATELY-ELEVATED BASELINE TRIGLYCERIDES ACROSS THE CARDIOVASCULAR RISK SPECTRUM. Journal of the American College of Cardiology. 75(11). 1980–1980. 1 indexed citations
7.
Leatherman, Sarah, Ryan Ferguson, Isabelle R. Weir, et al.. (2019). INCREASED RESIDUAL CARDIOVASCULAR RISK IN US VETERANS AND MONERATELY-ELEVATED BASELINE TRIGLYCERIDES AND WELL-CONTROLLED LDL-C LEVELS ON STATINS. Journal of the American College of Cardiology. 73(9). 1719–1719. 2 indexed citations
8.
Case, Brian C., Adam P. Bress, Paul Kolm, et al.. (2019). The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. Journal of clinical lipidology. 13(5). 754–761. 12 indexed citations
9.
Návar, Ann Marie, Neha J. Pagidipati, Hillary Mulder, et al.. (2019). TRIGLYCERIDES AS A RISK FACTOR FOR CORONARY HEART DISEASE: WHAT MEASURE AND WHAT CUTOFF?. Journal of the American College of Cardiology. 73(9). 1865–1865. 3 indexed citations
10.
Tóth, Peter P., Craig Granowitz, Michael Hüll, Amy Anderson, & Sephy Philip. (2019). Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids in Health and Disease. 18(1). 175–175. 53 indexed citations
11.
Ballantyne, Christie M., Mehar S. Manku, Harold Bays, et al.. (2019). Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study. Cardiology and Therapy. 8(1). 79–90. 18 indexed citations
12.
13.
Fan, Wenjun, Sephy Philip, Peter P. Tóth, Craig Granowitz, & Nathan D. Wong. (2019). Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007–2014. Cardiology Journal. 26(5). 604–606. 6 indexed citations
14.
Fan, Wenjun, Sephy Philip, Craig Granowitz, Peter P. Tóth, & Nathan D. Wong. (2018). Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. Journal of clinical lipidology. 13(1). 100–108. 49 indexed citations
15.
Bays, Harold, Christie M. Ballantyne, Ralph T. Doyle, Rebecca A. Juliano, & Sephy Philip. (2016). Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins & Other Lipid Mediators. 125. 57–64. 38 indexed citations
16.
Ballantyne, Christie M., Harold Bays, Rene A. Braeckman, et al.. (2016). Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. Journal of clinical lipidology. 10(3). 635–645.e1. 40 indexed citations
17.
Mosca, Lori, Christie M. Ballantyne, Harold Bays, et al.. (2016). Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). The American Journal of Cardiology. 119(3). 397–403. 11 indexed citations
18.
Bays, Harold, Christie M. Ballantyne, Rene A. Braeckman, et al.. (2015). Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 13(6). 239–247. 19 indexed citations
19.
Hejna, James, et al.. (2007). The hSNM1 protein is a DNA 5'-exonuclease. Nucleic Acids Research. 35(18). 6115–6123. 39 indexed citations
20.
Philip, Sephy. (2000). Angiogenesis Inhibitors in Oncology. Cancer Practice. 8(3). 148–150. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James M. Backes Breakdown of academic impact, for papers by P. Mata Breakdown of academic impact, for papers by David Colquhoun Breakdown of academic impact, for papers by Helmut Schulte Breakdown of academic impact, for papers by Bernard M. Wolfe Breakdown of academic impact, for papers by Andrey V. Susekov Breakdown of academic impact, for papers by Sion Roy Breakdown of academic impact, for papers by Estelle Nobécourt Breakdown of academic impact, for papers by Giacomo Levantesi Breakdown of academic impact, for papers by Christos V. Rizos
Rankless by CCL
2026